===== Multiple Sclerosis =====
Multiple sclerosis is a common condition of young people and mature adults, affecting nearly a million Americans. The most common form is Relapsing-Remitting, but there are also Primary Progressive, Secondary Progressive, and Progressive-Relapsing subtypes. New trials are directed against the disease itself, hoping to slow progression, or against particular symptoms like spasticity (stiffness of muscles and limbs).
^ Condition ^ Type of Drug ^ Phase ^ Comparator ^ Duration ^ Open Label Extension ^
| Relapsing-Remitting Multiple Sclerosis | Oral DHODH inhibitor | III | None | 72 weeks | Up to 8 years |
| Multiple Sclerosis | Oral Nerve Repair Agent | I | None | 48 weeks | Anticipated |
====== Response Form ======
If you or a loved one is interested in participating in one of our trials, please
contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research
Coordinators will contact you as soon as possible. Thank you for your interest in our research!
- Stephen S. Flitman, MD, Medical Director